RSPO1, A Potent Inducer of Pancreatic Beta Cell Neogenesis

    May 2025 in “ Cell Reports Medicine ”
    Serena Silvano, Tiziana Napolitano, Magali Plaisant, Anette Sousa-De-Veiga, Hugo Fofo, Chaïma Ayachi, Benoit Allegrini, Samah Rekima, Estelle Pichery, Jérôme Becam, Valentin Lepage, Caroline Treins, Laura Etasse, Loan Tran, Julien Thévenet, Gianni Pasquetti, Julie Kerr‐Conte, François Pattou, Paolo Botti, Arduino Arduini, Jacques Mizrahi, Benjamin Charles, Patrick Collombat
    TLDR RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.
    The study identifies RSPO1 as a potent inducer of pancreatic β cell neogenesis, offering promise for diabetes treatment. RSPO1, an agonist of the Wnt/β-catenin pathway, significantly increases β cell replication in vitro, ex vivo, and in vivo. It activates Wnt/β-catenin signaling in β cells, countering chemically induced or autoimmune-mediated diabetes. An optimized RSPO1 analog, administered weekly, also prevents diabetes in vivo. Additionally, RSPO1 treatment of transplanted human islets results in a 2.78-fold increase in functional human β cell numbers within 60 days. These findings suggest RSPO1 could be a breakthrough in developing alternative diabetes therapies.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results